EV Biologics (EV Biologics) EPS (Basic) : $-3.55 (TTM As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics EPS (Basic)?

EV Biologics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2017 was $-0.95. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2017 was $-3.55.

EV Biologics's EPS (Diluted) for the three months ended in Dec. 2017 was $-0.95. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was $-3.55.

EV Biologics's EPS without NRI for the three months ended in Dec. 2017 was $18.45. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2017 was 15.85.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

EV Biologics EPS (Basic) Historical Data

The historical data trend for EV Biologics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics EPS (Basic) Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

EPS (Basic)

4.23

4.50

5.42

-22.30

-3.08

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
EPS (Basic)	Get a 7-Day Free Trial												-25.75	-1.20	-111.50	-2.60	-0.95

EV Biologics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

EV Biologics's Basic EPS for the fiscal year that ended in Jun. 2017 is calculated as

Basic EPS (A: Jun. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.43	-	0)	/	2.410
	=	-3.08

EV Biologics's Basic EPS for the quarter that ended in Dec. 2017 is calculated as

Basic EPS (Q: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.239	-	0)	/	2.410
	=	-0.93

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.55

EV Biologics (OTCPK:YECO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

EV Biologics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of EV Biologics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » EPS (Basic)

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3